

# Gabriel Schnetzler

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9522110/gabriel-schnetzler-publications-by-citations.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

19 papers	188 citations	8 h-index	13 g-index
23 ext. papers	211 ext. citations	3.4 avg, IF	2.1 L-index

#	Paper	IF	Citations
19	Characteristics, behaviors, and attitudes of men bypassing the healthcare system when obtaining phosphodiesterase type 5 inhibitors. <i>Journal of Sexual Medicine</i> , <b>2010</b> , 7, 1237-46	1.1	44
18	Emotional changes in men treated with sildenafil citrate for erectile dysfunction: a double-blind, placebo-controlled clinical trial. <i>Journal of Sexual Medicine</i> , <b>2009</b> , 6, 3469-77	1.1	25
17	Scoring correspondence in outcomes related to erectile dysfunction treatment on a 4-point scale (SCORE-4). <i>Journal of Sexual Medicine</i> , <b>2009</b> , 6, 809-19	1.1	24
16	Interrelationship of sildenafil treatment effects on the physiological and psychosocial aspects of erectile dysfunction of mixed or organic etiology. <i>Journal of Sexual Medicine</i> , <b>2010</b> , 7, 3170-8	1.1	24
15	Malaria chemoprophylaxis regimens: a descriptive drug utilization study. <i>Travel Medicine and Infectious Disease</i> , <b>2014</b> , 12, 718-25	8.4	15
14	The EPIFARM study: an observational study in 574 community pharmacies in Spain characterizing patient profiles of men asking for erectile dysfunction medication. <i>Journal of Sexual Medicine</i> , <b>2010</b> , 7, 3153-60	1.1	12
13	Pharmaceutical quality of eight generics of ceftriaxone preparation for injection in Eastern Asia. <i>Journal of Chemotherapy</i> , <b>2015</b> , 27, 337-42	2.3	9
12	Understanding the effects of sildenafil treatment on erection maintenance and erection hardness. <i>Journal of Sexual Medicine</i> , <b>2010</b> , 7, 2184-2191	1.1	8
11	A feasibility study comparing pharmacist and physician recommendations for sildenafil treatment. <i>Journal of Sexual Medicine</i> , <b>2011</b> , 8, 1463-71	1.1	5
10	Comparative benefit of malaria chemoprophylaxis modelled in United Kingdom travellers. <i>Travel Medicine and Infectious Disease</i> , <b>2014</b> , 12, 726-32	8.4	4
9	The ability of the general male public to assess their suitability to take 50-mg sildenafil: an assessment of the comprehension of patient information materials via internet survey. <i>Journal of Sexual Medicine</i> , <b>2011</b> , 8, 2038-47	1.1	4
8	The ability of men to assess their suitability to take a phosphodiesterase type 5 inhibitor: an assessment of the comprehension of patient information materials. <i>Journal of Sexual Medicine</i> , <b>2010</b> , 7, 2217-2225	1.1	4
7	Validation of a treatment satisfaction questionnaire in non-Hodgkin lymphoma: assessing the change from intravenous to subcutaneous administration of rituximab. <i>Patient Preference and Adherence</i> , <b>2016</b> , 10, 1767-1776	2.4	4
6	Evolution to a Competency-Based Training Curriculum for Pharmaceutical Medicine Physicians in Switzerland. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 164	5.6	2
5	Preclinical characterization of a next generation brain permeable, paradox breaker BRAF inhibitor. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	2
4	Model-based approach for methoxy polyethylene glycol-epoetin beta drug development in paediatric patients with anaemia of chronic kidney disease. <i>British Journal of Clinical Pharmacology</i> , <b>2020</b> , 86, 801-811	3.8	1
3	Vismodegib (ERIVEDGE) pregnancy prevention programme: assessment of risk awareness. <i>Journal of Dermatological Treatment</i> , <b>2020</b> , 1-7	2.8	0

- 2      Testosterone measurement - mandatory in ALL men with ED - a response. *International Journal of Clinical Practice*, **2012**, 66, 113-114      2.9
- 1      Overview of Guidelines and Recommendations for the Planning, Conduct and Reporting of Company-Sponsored Observational, Noninterventional Studies in Europe. *Pharmaceutical Medicine*, **2011**, 25, 235-244      2.3